Meador Kimford J
Department of Neurology & Neurological Sciences, Stanford University, Stanford CA.
Epilepsy Behav Case Rep. 2014 Jan 1;2:54-56. doi: 10.1016/j.ebcr.2014.03.001.
An adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reduction in seizures when treated with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. The seizure reduction may be partly to reductions associated with aging in Dravet patients, but it appears to be due at least in part to the fluoxetine. A prior preliminary study reported that fenfluramine reduces seizures in patients with Dravet syndrome. Fenfluramine may produce this effect by increasing serotonin brain levels, and SSRIs have been found to possess antiepileptic properties in animal models of epilepsy. Given the known cardiac risks of fenfluramine, consideration of randomized clinical trials with SSRIs should be considered in Dravet syndrome and other epilepsies.
一名患有德拉韦综合征（记录有SCN1A突变）的成年女性在使用选择性5-羟色胺再摄取抑制剂（SSRI）氟西汀治疗时癫痫发作显著减少。癫痫发作减少可能部分与德拉韦综合征患者的年龄增长有关，但似乎至少部分归因于氟西汀。一项先前的初步研究报告称，芬氟拉明可减少德拉韦综合征患者的癫痫发作。芬氟拉明可能通过提高大脑中5-羟色胺水平产生这种作用，并且已发现在癫痫动物模型中SSRI具有抗癫痫特性。鉴于芬氟拉明已知的心脏风险，对于德拉韦综合征和其他癫痫，应考虑进行关于SSRI的随机临床试验。
